Outcome of rapid disease progression in the treatment break following cytoreductive nephrectomy (CN) after presurgical sunitinib in patients with primary metastatic renal cell carcinoma (RCC).
Axel Bex
Consultant or Advisory Role - Pfizer
Thomas Powles
Consultant or Advisory Role - Pfizer
Christian U. Blank
No relevant relationships to disclose
Simon Chowdhury
No relevant relationships to disclose
Simon Horenblas
No relevant relationships to disclose
John Peters
No relevant relationships to disclose
Ekaterini Boleti
No relevant relationships to disclose
John B. A. G. Haanen
Consultant or Advisory Role - Pfizer